Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the United States for all approved indications.
Pharmacy technology and automation companies have ramped up their offerings, and many are embedding AI in their platforms to ensure pharmacists can go beyond lick, stick and pour.